{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:57:06Z","timestamp":1790193426816,"version":"4.1.0"},"reference-count":17,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Primary biliary cholangitis (PBC), also known as primary biliary cirrhosis, is an autoimmune disease of the liver characterized by anti-mitochondrial antibodies (AMA) in 90%\u201395% of patients. The aim of this study was to evaluate the diagnostic value of several serum biomarkers in patients with PBC but negative for AMA. Some antinuclear antibodies (ANA) pattern, detected by indirect immunofluorescence (IIF), such as multiple nuclear dot (MND) and rim-like patterns are well-known to be specific for PBC. The corresponding nuclear antigens are the components of the nuclear pore complex (Gp210 for rim-like pattern) and Sp100, PML proteins (for MND pattern) detectable by immunoblotting and ELISA methods. More recently, new biomarkers have been evaluated in order to improve the diagnostic sensitivity, such as kelch-like 12 (KLHL12) and hexokinase-1. Considering these different serum biomarkers, studies evaluating their diagnostic role in AMA-negative PBC patients compared to AMA-positive ones and controls were included in this review. Pooled sensitivity and specificity were 37% and 85%, respectively. The overall PPV and NPV mean values were 45% and 83%. Even if all biomarkers are very specific for PBC, the overall sensitivity was poor and therefore is necessary to identify a marker with a greater sensitivity for PBC in AMA-negative patients.<\/jats:p>","DOI":"10.1515\/cclm-2017-0249","type":"journal-article","created":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T10:01:09Z","timestamp":1500631269000},"page":"25-31","source":"Crossref","is-referenced-by-count":38,"title":["The diagnostic accuracy of biomarkers for diagnosis of primary biliary cholangitis (PBC) in anti-mitochondrial antibody (AMA)-negative PBC patients: a review of literature"],"prefix":"10.1515","volume":"56","author":[{"given":"Federica","family":"de Liso","sequence":"first","affiliation":[{"name":"Laboratorio di analisi chimico cliniche e microbiologia, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Via Francesco Sforza 35 , Milan , Italy , Phone: +255032582, Fax: +255032397"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Matinato","sequence":"additional","affiliation":[{"name":"Laboratorio di analisi chimico cliniche e microbiologia, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milan , Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Ronchi","sequence":"additional","affiliation":[{"name":"Laboratorio di analisi chimico cliniche e microbiologia, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milan , Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Maiavacca","sequence":"additional","affiliation":[{"name":"Laboratorio di analisi chimico cliniche e microbiologia, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milan , Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2017,7,21]]},"reference":[{"key":"2021021219460130385_j_cclm-2017-0249_ref_001_w2aab3b7c75b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Leuschner U. Primary biliary cirrhosis \u2013 presentation and diagnosis. Clin Liver Dis 2003;7:741\u201358.","DOI":"10.1016\/S1089-3261(03)00101-6"},{"key":"2021021219460130385_j_cclm-2017-0249_ref_002_w2aab3b7c75b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Granito A, Yang WH, Muratori L, Lim MJ, Nakajima A, Ferri S, et al. PML nuclear body component sp140 is a novel autoantigen in primary biliary cirrhosis. Am J Gastroenterol 2010;105:125\u201331.","DOI":"10.1038\/ajg.2009.596"},{"key":"2021021219460130385_j_cclm-2017-0249_ref_003_w2aab3b7c75b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Liu B, Shi XH, Zhang FC, Zhang W, Gao LX. Antimitochondrial antibody-negative primary biliary cirrhosis: a subset of primary biliary cirrhosis. Liver Int 2008;28:233\u20139.","DOI":"10.1111\/j.1478-3231.2007.01651.x"},{"key":"2021021219460130385_j_cclm-2017-0249_ref_004_w2aab3b7c75b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Gao L, Tian X, Liu B, Zhang F. The value of antinuclear antibodies in primary biliary cirrhosis. Clin Exp Med 2008;8:9\u201315.","DOI":"10.1007\/s10238-008-0150-6"},{"key":"2021021219460130385_j_cclm-2017-0249_ref_005_w2aab3b7c75b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Granito A, Muratori P, Muratori L, Pappas G, Cassani F, Worthington J, et al. Antinuclear antibodies giving the \u2018multiple nuclear dots\u2019 or the \u2018rim-like\/membranous\u2019 patterns: diagnostic accuracy for primary biliary cirrhosis. Aliment Pharmacol Ther 2006;24:1575\u201383.","DOI":"10.1111\/j.1365-2036.2006.03172.x"},{"key":"2021021219460130385_j_cclm-2017-0249_ref_006_w2aab3b7c75b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Ueno Y, Ishii M, Takahashi S, Mano Y, Yahagi K, Kisara N, et al. Primary biliary cirrhosis with antibody against carbonic anhydrase II associates with distinct immunological backgrounds. Hepatol Res 2001;20:18\u201327.","DOI":"10.1016\/S1386-6346(00)00128-5"},{"key":"2021021219460130385_j_cclm-2017-0249_ref_007_w2aab3b7c75b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Muratori P, Muratori L, Lenzi M, Bianchi FB. Antibodies to carbonic anhydrase in autoimmune cholangiopathy. Gastroenterolgy 1997;112:1053\u20134.","DOI":"10.1053\/gast.1997.v112.agast971053"},{"key":"2021021219460130385_j_cclm-2017-0249_ref_008_w2aab3b7c75b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Gordon SC, Quattrociocchi-Longe TM, Khan BA, Kodali VP, Chen J, Silverman AL, et al. Antibodies to carbonic anhydrase in patients with immune cholangiopathies. Gastroenterology 1995;108:1802\u20139.","DOI":"10.1016\/0016-5085(95)90143-4"},{"key":"2021021219460130385_j_cclm-2017-0249_ref_009_w2aab3b7c75b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Norman GL, Yang CY, Ostendorff HP, Shums Z, Lim MJ, Wang J, et al. Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis. Liver Int 2015;35:642\u201351.","DOI":"10.1111\/liv.12690"},{"key":"2021021219460130385_j_cclm-2017-0249_ref_010_w2aab3b7c75b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"2021021219460130385_j_cclm-2017-0249_ref_011_w2aab3b7c75b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the study of liver disease practice guidelines. Hepatology 2000;31:1005\u201313.","DOI":"10.1053\/he.2000.5984"},{"key":"2021021219460130385_j_cclm-2017-0249_ref_012_w2aab3b7c75b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Rigopoulou EI, Davies ET, Pares A, Zachou K, Liaskos C, Bogdanos DP, et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 2005;54:528\u201332.","DOI":"10.1136\/gut.2003.036558"},{"key":"2021021219460130385_j_cclm-2017-0249_ref_013_w2aab3b7c75b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Muratori P, Muratori L, Ferrari R, Cassani F, Bianchi G, Lenzi M, et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003;98:431\u20137.","DOI":"10.1111\/j.1572-0241.2003.07257.x"},{"key":"2021021219460130385_j_cclm-2017-0249_ref_014_w2aab3b7c75b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Invernizzi P, Crosignani A, Battezzati PM, Covini G, De Valle G, Larghi A, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997;25:1090\u20135.","DOI":"10.1002\/hep.510250507"},{"key":"2021021219460130385_j_cclm-2017-0249_ref_015_w2aab3b7c75b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Comay D, Cauch-Dudek K, Hemphill D, Diamandis E, Wanless I, Heathcote EJ. Are antibodies to carbonic anhydrase II specific for anti-mitochondrial antibody-negative primary biliary cirrhosis? Dig Dis Sci 2000;45:2018\u201321.","DOI":"10.1023\/A:1005548126211"},{"key":"2021021219460130385_j_cclm-2017-0249_ref_016_w2aab3b7c75b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Invernizzi P, Battezzati PM, Crosignani A, Zermiani P, Bignotto M, Del Papa N, et al. Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status. Clin Exp Immunol 1998;114:448\u201354.","DOI":"10.1046\/j.1365-2249.1998.00735.x"},{"key":"2021021219460130385_j_cclm-2017-0249_ref_017_w2aab3b7c75b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Bizzaro N, Covini G, Rosina F, Muratori P, Tonutti E, Villalta D, et al. Overcoming a \u201cportable\u201d diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature. Clin Rev Allergy Immunol 2012;42:288\u201397.","DOI":"10.1007\/s12016-010-8234-y"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2018.56.issue-1\/cclm-2017-0249\/cclm-2017-0249.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2017-0249\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2017-0249\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T23:57:54Z","timestamp":1619049474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2017-0249\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,21]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,7,21]]},"published-print":{"date-parts":[[2017,11,27]]}},"alternative-id":["10.1515\/cclm-2017-0249"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2017-0249","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7,21]]}}}